Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | ESRRB | O95718 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17236358 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2CA1CA2CA14MMP8 | |
| SCHEMBL7955830 | 0.98 | SMN1; SMN2 (0.38) | SMN1; SMN2CA1CA2CA14MMP8 | |
| SCHEMBL17236363 | 0.84 | PIK3CD (0.41) | SMN1; SMN2CA1CA2CA14MMP8 | |
| SCHEMBL14459291 | 0.82 | SMN1; SMN2 (0.37) | SMN1; SMN2CA1CA2CA14MMP8 | |
| SCHEMBL20499832 | 0.81 | MMP8 (0.32) | MMP8 | |
| SCHEMBL20921735 | 0.80 | MMP8 (0.33) | MMP8 | |
| SCHEMBL13227918 | 0.80 | CA1 (0.38) | SMN1; SMN2CA1CA2CA14MMP8 | |
| SCHEMBL28690616 | 0.80 | SMN1; SMN2 (0.35) | SMN1; SMN2CA1CA2CA14MMP8 | |
| SCHEMBL17278939 | 0.80 | ACACB (0.37) | SMN1; SMN2CA1CA2CA14MMP8 | |
| SCHEMBL10838592 | 0.80 | MMP8 (0.37) | SMN1; SMN2CA1CA2CA14MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-11643657-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-09 | — | — | US | disclosed |
| US-20180216108-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-08-02 | — | — | US | disclosed |
| US-20180216107-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-08-02 | — | — | US | disclosed |
| US-9982257-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2018-05-29 | — | — | US | disclosed |
| US-9885037-B2 | — | — | 2018-02-06 | — | — | US | disclosed |
| US-20170275621-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20170037399-A1 | CHIRAL DESIGN | WAVE LIFE SCIENCES LTD. (SG) | 2017-02-09 | — | — | US | disclosed |
| US-20150211006-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | SMN1; SMN2 4550/4885CA1 3604/4885CA2 711/4885 |
| US-20170275621-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | SMN1; SMN2 695/4885CA1 467/4885CA2 904/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | SMN1; SMN2 695/4885CA1 467/4885CA2 904/4885 |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | SMN1; SMN2 457/4885CA1 1307/4885CA2 1573/4885 |
| US-20150211006-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | SMN1; SMN2 695/4885CA1 467/4885CA2 904/4885 |
| US-11643657-B2 | Chiral control | RNGTT, POLI, NSUN3 | SMN1; SMN2 695/4885CA1 467/4885CA2 904/4885 |
| US-20180216108-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, POLRMT | SMN1; SMN2 320/4885CA1 327/4885CA2 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.